Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy?: a systematic review and meta-analysis
Purpose: This systematic review evaluates the efficacy of neurokinin-1 receptor antagonists (NK1RAs) for the prevention of chemotherapy-induced nausea and vomiting (CINV) in moderately emetogenic chemotherapy (MEC) excluding anthracycline-cyclophosphamide-based regimens. Methods: A systematic review...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2018
|
| In: |
Supportive care in cancer
Year: 2018, Volume: 26, Issue: 1, Pages: 21-32 |
| ISSN: | 1433-7339 |
| DOI: | 10.1007/s00520-017-3857-7 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1007/s00520-017-3857-7 Verlag, Volltext: https://doi.org/10.1007/s00520-017-3857-7 
|
| Author Notes: | Karin Jordan, Luisa Blättermann, Axel Hinke, Carsten Müller-Tidow, Franziska Jahn |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1580192920 | ||
| 003 | DE-627 | ||
| 005 | 20241126100543.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180820s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00520-017-3857-7 |2 doi | |
| 035 | |a (DE-627)1580192920 | ||
| 035 | |a (DE-576)510192920 | ||
| 035 | |a (DE-599)BSZ510192920 | ||
| 035 | |a (OCoLC)1341017116 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Jordan, Karin |d 1974- |e VerfasserIn |0 (DE-588)123243327 |0 (DE-627)706224078 |0 (DE-576)293619174 |4 aut | |
| 245 | 1 | 0 | |a Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy? |b a systematic review and meta-analysis |c Karin Jordan, Luisa Blättermann, Axel Hinke, Carsten Müller-Tidow, Franziska Jahn |
| 264 | 1 | |c 2018 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 20.08.2018 | ||
| 500 | |a Online veröffentlicht: 31. August 2017 | ||
| 520 | |a Purpose: This systematic review evaluates the efficacy of neurokinin-1 receptor antagonists (NK1RAs) for the prevention of chemotherapy-induced nausea and vomiting (CINV) in moderately emetogenic chemotherapy (MEC) excluding anthracycline-cyclophosphamide-based regimens. Methods: A systematic review of MEDLINE (via PubMed and OVID) and Central databases, plus major oncology conferences, identified randomized trials evaluating NK1RAs in combination with a 5-HT3 RA plus a glucocorticoid for management of CINV. Efficacy endpoints were complete response (CR), no emesis and no nausea rates. Data were analyzed using a random effects model. Results: Sixteen trials (3848 patients) were identified. Results were separately analyzed for (a) pure MEC regimens (excluding regimens containing carboplatin or oxaliplatin), (b) carboplatin-based regimens, and (c) oxaliplatin-based regimens. (a) Two trials (abstracts) enrolled 715 patients. The odds ratio for overall CR with the addition of an NK1-RA was 1.46 (95% 1.06-2.02; p = 0.02) with an absolute risk difference (RD) of 8%. (b) Nine trials (1790 patients) were identified. The OR for achieving an overall CR was 1.96 (95% CI 1.57-2.45; p < 0.00001) in favor of the NK1RA containing regimen with an RD of 15%. (c) Three trials (1190 patients) were identified. The OR for achieving an overall CR was 1.34 (95% CI 0.88-2.04; p = 0.17) not reaching statistical significance with a RD of 4%. Conclusion: Clear clinically significant benefit was seen with the addition of NK1RAs in carboplatin-based chemotherapy. A global benefit of an NK1RA containing regimen for the whole MEC category cannot be attested yet and warrants more randomized trials exclusively testing pure MEC regimens without carboplatin. | ||
| 650 | 4 | |a Carboplatin | |
| 650 | 4 | |a Chemotherapy-induced nausea and vomiting (CINV) | |
| 650 | 4 | |a Moderately emetogenic chemotherapy (MEC) | |
| 650 | 4 | |a Neurokinin-1 receptor antagonist (NK1RA) | |
| 650 | 4 | |a Oxaliplatin | |
| 700 | 1 | |a Müller-Tidow, Carsten |d 1968- |e VerfasserIn |0 (DE-588)1015101798 |0 (DE-627)705330230 |0 (DE-576)351197893 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Supportive care in cancer |d Berlin : Springer, 1993 |g 26(2018), 1, Seite 21-32 |h Online-Ressource |w (DE-627)254909574 |w (DE-600)1463166-0 |w (DE-576)074754076 |x 1433-7339 |7 nnas |a Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy? a systematic review and meta-analysis |
| 773 | 1 | 8 | |g volume:26 |g year:2018 |g number:1 |g pages:21-32 |g extent:12 |a Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy? a systematic review and meta-analysis |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00520-017-3857-7 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00520-017-3857-7 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180820 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 1015101798 |a Müller-Tidow, Carsten |m 1015101798:Müller-Tidow, Carsten |d 910000 |d 910100 |e 910000PM1015101798 |e 910100PM1015101798 |k 0/910000/ |k 1/910000/910100/ |p 4 | ||
| 998 | |g 123243327 |a Jordan, Karin |m 123243327:Jordan, Karin |d 910000 |d 910100 |e 910000PJ123243327 |e 910100PJ123243327 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1580192920 |e 3022612737 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"12 S."}],"recId":"1580192920","note":["Gesehen am 20.08.2018","Online veröffentlicht: 31. August 2017"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"title":[{"title_sort":"Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy?","title":"Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy?","subtitle":"a systematic review and meta-analysis"}],"person":[{"role":"aut","given":"Karin","family":"Jordan","display":"Jordan, Karin"},{"role":"aut","given":"Carsten","family":"Müller-Tidow","display":"Müller-Tidow, Carsten"}],"relHost":[{"note":["Gesehen am 06.12.05"],"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"title":[{"subtitle":"official journal of the Multinational Association of Supportive Care in Cancer","title":"Supportive care in cancer","title_sort":"Supportive care in cancer"}],"part":{"pages":"21-32","issue":"1","extent":"12","text":"26(2018), 1, Seite 21-32","year":"2018","volume":"26"},"id":{"zdb":["1463166-0"],"eki":["254909574"],"issn":["1433-7339"]},"pubHistory":["1.1993 -"],"origin":[{"publisher":"Springer","dateIssuedKey":"1993","publisherPlace":"Berlin ; Heidelberg ; New York,NY","dateIssuedDisp":"1993-"}],"disp":"Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy? a systematic review and meta-analysisSupportive care in cancer","physDesc":[{"extent":"Online-Ressource"}],"recId":"254909574"}],"origin":[{"dateIssuedKey":"2018","dateIssuedDisp":"2018"}],"id":{"doi":["10.1007/s00520-017-3857-7"],"eki":["1580192920"]},"name":{"displayForm":["Karin Jordan, Luisa Blättermann, Axel Hinke, Carsten Müller-Tidow, Franziska Jahn"]}} | ||
| SRT | |a JORDANKARIISTHEADDIT2018 | ||